Cytomel (Liothyronine) Cost in Washington 2026

What Does Liothyronine Actually Cost in Washington?

Generic liothyronine tablets cost Washington patients roughly $35 per month when a free discount card such as GoodRx or RxSaver is applied at most major retail chains. Without any discount, the same 30-day supply often appears at $60 to $90 depending on dose and pharmacy. Brand-name Cytomel carries a manufacturer list price near $120 per month, though almost no cash-pay patient pays that figure after coupons.

Liothyronine is synthetic triiodothyronine (T3), the more metabolically active thyroid hormone. The FDA approved Cytomel for hypothyroidism, pituitary TSH suppression, and thyroid diagnostic testing. Because generic versions entered the market years ago, the drug is now available from multiple manufacturers, which drives competition and keeps retail prices well below the list price.

Price varies by dose. A 5 mcg tablet supply costs less than a 25 mcg or 50 mcg supply at many pharmacies, so patients titrating upward should re-check discount prices at each new strength. Seattle-area Costco, Walgreens, Rite Aid, and Fred Meyer pharmacies all carry generic liothyronine; prices differ by as much as 40 percent between chains for the same 30-day supply. Checking three or four pharmacies before filling saves real money.

Washington does not currently cap the out-of-pocket cost of thyroid medications the way some states cap insulin, so cash-pay patients bear the full retail price minus any coupon applied. GoodRx pricing data from early 2025 shows generic liothyronine 25 mcg (30 tablets) as low as $16 at select Washington pharmacies, confirming that discount programs produce meaningful savings over sticker price.

Does Washington Medicaid (Apple Health) Cover Liothyronine?

Washington Apple Health covers liothyronine for hypothyroidism as an adjunct therapy, but a prior authorization (PA) request must be approved before the claim processes. Most managed care organizations (MCOs) under Apple Health, Molina, Community Health Plan of Washington, and Coordinated Care, follow a shared preferred drug list that lists levothyroxine (T4 monotherapy) as the first-line agent.

Prescribers must document that levothyroxine alone failed to normalize the patient's symptoms or TSH/free-T3 levels before submitting the PA. The Washington State Health Care Authority publishes its preferred drug list and PA criteria on its website; as of 2025, the clinical justification threshold requires at least one trial of levothyroxine at an optimized dose. A 2019 survey of thyroid patients published in the Journal of Clinical Endocrinology and Metabolism found that roughly 15 percent of hypothyroid patients on T4 monotherapy report persistent symptoms despite normal TSH, which is the population most likely to pursue combination T3 therapy and therefore most likely to need a PA.

Once approved, Apple Health's copay for generic liothyronine is $1 to $4 per fill for most enrollees, making it far cheaper than any cash-pay route. PA approvals typically cover 12 months before renewal. Patients should ask their prescriber's office to submit the PA documentation at the same visit they receive the prescription, avoiding the gap that occurs when the pharmacy triggers a PA rejection at point of sale.

Dual-eligible patients (Medicare and Medicaid) follow Medicare Part D rules first. Part D formularies vary; patients should use Medicare's Plan Finder tool to confirm their specific plan's tier placement and cost-sharing before assuming Apple Health will pick up the remainder.

Is Compounded Liothyronine Legal in Washington?

Compounded liothyronine T3 is legal in Washington when prepared by a state-licensed 503A pharmacy operating under a valid patient-specific prescription. No special state waiver is required beyond the standard compounding pharmacy license issued by the Washington State Department of Health Board of Pharmacy.

503A pharmacies compound for individual patients based on a prescriber's order. They may not manufacture large batches for general sale, which separates them from 503B outsourcing facilities. The FDA's guidance on compounded thyroid preparations notes that liothyronine is not a commercially unavailable drug, meaning compounding is permissible under 503A rules when a prescriber documents a clinical reason the commercial product does not meet the patient's needs, such as an allergy to a tablet filler or the need for a non-standard dose strength.

Compounded liothyronine in Washington runs approximately $40 per month, slightly above the cheapest generic cash-pay option but potentially below brand-name cost. Some patients prefer slow-release compounded T3 formulations. A controlled crossover study by Idrees et al. (2020) in Thyroid found no statistically significant difference in symptom scores between immediate-release and sustained-release compounded T3, though some clinicians still prefer the sustained-release form for patients who experience palpitations on a single morning dose. That preference is clinical, not regulatory.

The Washington Board of Pharmacy audits compounding pharmacies on a regular cycle. Patients should verify that any pharmacy dispensing compounded T3 holds a current Washington state license, which is searchable on the DOH provider credential search tool.

Can a Washington Patient Get Liothyronine via Telehealth?

Telehealth prescribing of liothyronine is fully legal in Washington State as of 2026. Washington expanded its telehealth parity law (RCW 48.43.735) to require that insurers reimburse telehealth visits at the same rate as in-person visits, which keeps telehealth affordable for patients seeking thyroid management without traveling to a clinic.

A Washington-licensed prescriber may issue a liothyronine prescription after a synchronous audio-video consultation without a prior in-person visit, provided the prescriber meets the standard of care for thyroid evaluation, which includes reviewing recent TSH, free T4, and free T3 lab values. ATA (American Thyroid Association) guidelines recommend measuring serum TSH as the primary screening test and free T3 when combination therapy is being considered. Telehealth providers typically require patients to upload lab results or order them through a partner lab before the prescription is written.

HealthRX clinicians licensed in Washington follow this same lab-first protocol. Prescriptions generated via telehealth are transmitted electronically to any Washington pharmacy the patient chooses, including mail-order pharmacies, which may offer 90-day supply pricing that further reduces per-dose cost.

Patients in rural Washington counties, including Ferry, Pend Oreille, and Garfield, where endocrinologists are sparse, benefit most from telehealth access. A 2022 study in the Journal of Rural Health found that telehealth thyroid consultations produced equivalent TSH normalization rates compared to in-person follow-up visits over 12 months (PMID 34862645).

Which Insurance Plans Cover Liothyronine in Washington?

Most commercial insurance plans in Washington cover generic liothyronine on Tier 1 or Tier 2 of their formulary, placing it at a $5 to $30 copay per 30-day fill. Brand-name Cytomel typically lands on Tier 3 or higher, where copays range from $40 to over $100, making the generic the clear financial choice for insured patients.

Major carriers operating in Washington's individual and small-group markets, including Premera Blue Cross, Regence BlueShield, Kaiser Permanente Washington, and Molina Healthcare, all list generic liothyronine on their 2025 to 2026 formularies. Patients should confirm tier placement by entering the drug name on their plan's formulary search tool, because mid-year formulary updates can change cost-sharing without advance notice.

The American Thyroid Association's 2014 guidelines stated: "We recommend against the routine use of combination T4 and T3 therapy" but acknowledged that "some patients may prefer combination therapy", a nuance that insurers sometimes use to justify PA requirements for combination regimens. Patients already on levothyroxine who add liothyronine may face a separate PA review even when their plan previously approved levothyroxine without restrictions.

Employer-sponsored self-insured plans are regulated under ERISA, not Washington state insurance law, so they are not bound by Washington's formulary or parity rules. Employees on self-insured plans should contact their HR benefits team directly to confirm liothyronine coverage before filling.

What Is the Clinical Rationale for T3 Therapy, and Does It Affect Coverage Decisions?

The evidence base for combination T4/T3 therapy remains contested, which directly shapes how insurers and Medicaid programs write their PA criteria. Understanding the clinical argument helps patients and prescribers build a stronger PA submission.

Bunevicius et al. published the landmark 1999 NEJM trial showing that substituting 12.5 mcg of liothyronine for 50 mcg of levothyroxine improved mood and neuropsychological function in 33 hypothyroid patients on T4 monotherapy (PMID 9971864). That study triggered two decades of follow-up research. A 2019 meta-analysis in the European Journal of Endocrinology (Idrees et al.) pooling data from 26 trials found no overall quality-of-life benefit for combination therapy versus monotherapy across unselected hypothyroid patients, but did identify a subgroup preferring combination therapy. Insurers cite the negative pooled result; prescribers cite the subgroup signal. Both readings of the data are technically accurate.

The practical implication: a PA submission that describes a patient's persistent fatigue and low free-T3 despite optimized levothyroxine, and that references the Bunevicius subgroup finding, is more likely to succeed than a generic request. Including two TSH results and one free-T3 result in the PA package strengthens the clinical narrative.

The Endocrine Society's 2012 clinical practice guideline on hypothyroidism noted that "evidence is insufficient to recommend for or against the routine use of combination T4/T3 therapy", a neutral statement that neither endorses nor blocks coverage. Prescribers can cite this neutrality when pushing back on automatic PA denials.

How Do Discount Programs and Savings Cards Work for Washington Patients?

Several discount mechanisms reduce liothyronine costs for Washington patients who pay out of pocket or face high cost-sharing.

GoodRx and RxSaver are free browser and app tools that generate discount coupons accepted at most Washington pharmacies. They work by negotiating block pricing with pharmacy benefit managers. The discount cannot be combined with insurance, so patients should calculate whether their insurance copay or the GoodRx price is lower before choosing which to use at the counter. For patients on high-deductible plans who have not met their deductible, GoodRx typically wins.

Pfizer's patient assistance program covers Cytomel for uninsured or underinsured patients who meet income thresholds. Applications are submitted through Pfizer RxPathways online. Generic manufacturers do not typically offer savings cards, but NeedyMeds.org and RxAssist.org maintain updated listings of patient assistance programs for all generic liothyronine producers currently selling in the U.S. market.

A 2022 JAMA Internal Medicine study found that GoodRx coupons reduced out-of-pocket costs for common generic medications by a median of 52 percent compared to insurance cost-sharing for patients who had not met their deductible. That figure translates directly to liothyronine: a $70 cash-pay price at a Seattle Walgreens could drop to under $35 with a coupon.

Washington's Prescription Drug Assistance Program (PDAP), administered through the Washington State Department of Social and Health Services, provides additional cost support for residents who do not qualify for Medicaid but cannot afford their medications. PDAP is income-based and requires an application, but eligible patients can receive co-pay assistance on top of any discount card savings.

The HealthRX Washington Liothyronine Cost Decision Framework works as follows. First, confirm insurance status and look up your plan's formulary tier for generic liothyronine (NDC: 00054-8147). If the copay exceeds $35, compare against GoodRx at your preferred pharmacy, because the lower of the two numbers is your baseline. If you are uninsured and your income is below 200 percent of the federal poverty level, apply to PDAP and Pfizer RxPathways simultaneously. If your prescriber recommends compounded T3 for a documented clinical reason, expect to pay roughly $40 per month at a licensed Washington 503A pharmacy, and budget for a $20 to $40 compounding fee that may not be covered by insurance. For Apple Health enrollees, the PA route, though slower, produces the lowest final cost at $1 to $4 per fill.

How Does Liothyronine Dosing Affect Total Monthly Cost?

Dose strength affects price. Liothyronine is available commercially in 5 mcg, 25 mcg, and 50 mcg tablets. At most Washington pharmacies, the per-tablet price difference between 5 mcg and 25 mcg is small in absolute terms, so a patient requiring 25 mcg daily pays less per microgram than one requiring 5 mcg daily. Patients taking 50 mcg daily may be prescribed two 25 mcg tablets rather than one 50 mcg tablet, depending on their prescriber's preference and pharmacy stock.

The FDA label for liothyronine specifies a starting dose of 25 mcg per day for mild hypothyroidism, with adjustments in 25 mcg increments at two-week intervals, and a lower starting dose of 5 mcg per day for elderly patients or those with cardiovascular disease. Starting at the lower dose means lower initial costs, though most patients titrate upward over the first 60 days.

Twice-daily dosing, which some prescribers prefer to mimic the diurnal T3 rhythm, doubles the number of doses per month without changing the total daily dose. A patient taking 12.5 mcg twice daily uses the same total drug as one taking 25 mcg once daily, but may require tablets to be split, adding a minor logistical cost if a pill splitter is needed.

A pharmacokinetic study by Jonklaas et al. (2015) in Thyroid documented that oral liothyronine reaches peak serum T3 within two to four hours and has a half-life of approximately one day, supporting either once- or twice-daily schedules from a pharmacokinetic standpoint. The choice between schedules does not change cost meaningfully, but patients should confirm with their prescriber which schedule is documented on their prescription before filling to avoid a quantity mismatch at the pharmacy.

What Lab Monitoring Adds to the Total Cost of Liothyronine Therapy in Washington?

The drug cost alone understates the total expense of liothyronine therapy. Thyroid panel monitoring, typically TSH and free T3 at minimum, is required at initiation, at each dose change, and at least every six months once stable. In Washington, a cash-pay thyroid panel at a commercial lab (Quest Diagnostics or LabCorp) runs $35 to $90 depending on the panel ordered and any negotiated self-pay discount.

The ATA/AES clinical practice guidelines recommend checking TSH and free T3 approximately six to eight weeks after any dose change in patients on combination T4/T3 therapy. For a patient making two dose adjustments in year one, that adds two to four additional labs to the first-year cost, bringing total first-year monitoring costs to $70 to $360 depending on insurance status.

Patients with Apple Health coverage pay nothing for lab draws at contracted facilities. Commercial insurance patients with met deductibles typically pay a $10 to $30 lab copay per draw. Uninsured patients should ask their ordering provider to use the lab's cash-pay panel price rather than the list price, which is almost always lower when requested directly.

A 2021 study in JAMA Network Open found that patients who monitored thyroid function at recommended intervals were 2.3 times more likely to achieve stable TSH targets within 12 months compared to those who skipped follow-up labs, making the monitoring investment a cost-effective part of overall therapy rather than an optional add-on.